Cytokinetics 향후 성장

Future 기준 점검 2/6

Cytokinetics (는) 각각 연간 48.6% 및 47% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 50.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -88.8% 로 예상됩니다.

핵심 정보

48.6%

이익 성장률

50.18%

EPS 성장률

Biotechs 이익 성장	23.0%
매출 성장률	47.0%
향후 자기자본이익률	-88.79%
애널리스트 커버리지	Good
마지막 업데이트	07 Apr 2026

최근 향후 성장 업데이트

Recent updates

Need To Know: The Consensus Just Cut Its Cytokinetics, Incorporated (NASDAQ:CYTK) Estimates For 2026

Jan 27

Cytokinetics: Small Label Differences With Big Commercial Stakes

Dec 22

Precision Medicine And Late-stage Trials Will Expand Global Reach

Aug 10 Successful late-stage clinical trials, commercial readiness, and diversification in products position the company for strong growth and reduced dependence on a single therapy.

The Cytokinetics, Incorporated (NASDAQ:CYTK) Analysts Have Been Trimming Their Sales Forecasts

May 20

Cytokinetics Nears Approval: 'Buy' The New Potential Cardiology Franchise With Aficamten

Mar 16

Cytokinetics Aligns For U.S. Launch Amid HCM Market Evolution

Dec 31

Cytokinetics: On The Cusp Of Commercialization

Nov 14

이익 및 매출 성장 예측

NasdaqGS:CYTK - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	809	-305	-248	-359	14
12/31/2027	371	-643	-531	-560	17
12/31/2026	92	-820	-597	-684	18
12/31/2025	88	-785	-535	-510	N/A
9/30/2025	87	-752	-453	-433	N/A
6/30/2025	86	-606	-439	-427	N/A
3/31/2025	19	-615	-408	-398	N/A
12/31/2024	18	-590	-400	-396	N/A
9/30/2024	3	-576	-407	-404	N/A
6/30/2024	3	-545	-401	-399	N/A
3/31/2024	4	-531	-423	-422	N/A
12/31/2023	8	-526	-416	-414	N/A
9/30/2023	8	-527	-443	-438	N/A
6/30/2023	10	-540	-437	-426	N/A
3/31/2023	98	-431	-406	-395	N/A
12/31/2022	95	-389	-311	-300	N/A
9/30/2022	148	-282	-272	-246	N/A
6/30/2022	151	-216	-236	-201	N/A
3/31/2022	65	-258	-183	-140	N/A
12/31/2021	70	-215	-191	-143	N/A
9/30/2021	22	-229	-83	-46	N/A
6/30/2021	58	-156	-17	8	N/A
3/31/2021	59	-135	-7	10	N/A
12/31/2020	56	-127	-2	9	N/A
9/30/2020	54	-114	-68	-62	N/A
6/30/2020	19	-140	-101	-97	N/A
3/31/2020	22	-132	-98	-94	N/A
12/31/2019	27	-122	-94	-91	N/A
9/30/2019	31	-118	N/A	-84	N/A
6/30/2019	36	-110	N/A	-96	N/A
3/31/2019	35	-105	N/A	-98	N/A
12/31/2018	32	-106	N/A	-101	N/A
9/30/2018	22	-120	N/A	-113	N/A
6/30/2018	18	-131	N/A	-106	N/A
3/31/2018	14	-132	N/A	-111	N/A
12/31/2017	13	-128	N/A	-102	N/A
9/30/2017	47	-80	N/A	0	N/A
6/30/2017	99	-14	N/A	14	N/A
3/31/2017	102	3	N/A	34	N/A
12/31/2016	106	16	N/A	37	N/A
9/30/2016	83	0	N/A	-51	N/A
6/30/2016	32	-42	N/A	-49	N/A
3/31/2016	33	-41	N/A	-47	N/A
12/31/2015	29	-38	N/A	5	N/A
9/30/2015	41	-20	N/A	7	N/A
6/30/2015	42	-17	N/A	8	N/A

애널리스트 향후 성장 전망

수입 대 저축률: CYTK 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: CYTK 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: CYTK 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: CYTK 의 수익(연간 47%)이 US 시장(연간 10.4%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: CYTK 의 수익(연간 47%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: CYTK는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/04/08 00:32
종가	2026/04/08 00:00
수익	2025/12/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Cytokinetics, Incorporated는 35명의 분석가가 다루고 있습니다. 이 중 18명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Carter Gould	Barclays
Huidong Wang	Barclays
Emily Field	Barclays

Cytokinetics 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

Consensus revenue estimates fall by 25%

Price target increased by 8.8% to US$86.56

Consensus revenue estimates increase by 276%

Consensus revenue estimates decrease by 34%, EPS upgraded

Consensus revenue estimates fall by 26%

Consensus revenue estimates decrease by 16%

Recent updates

CEO, President & Director recently sold US$500k worth of stock

CEO, President & Director recently sold US$2.3m worth of stock

Consensus revenue estimates fall by 25%

Independent Director notifies of intention to sell stock

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Cytokinetics, Incorporated Announces European Commission Approval of MYQORZO®? (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cytokinetics, Incorporated to Report Q4, 2025 Results on Feb 24, 2026

Executive VP & Chief Commercial Officer exercised options and sold US$580k worth of stock

Need To Know: The Consensus Just Cut Its Cytokinetics, Incorporated (NASDAQ:CYTK) Estimates For 2026

Cytokinetics, Incorporated Announces MYQORZO (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Executive VP & Chief Commercial Officer exercised options and sold US$555k worth of stock

CEO, President & Director exercised options and sold US$1.9m worth of stock

Price target increased by 8.8% to US$86.56

Cytokinetics: Small Label Differences With Big Commercial Stakes

Cytokinetics, Incorporated Announces FDA Approval of MYQORZO (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Cytokinetics Announces Nmpa Approval of Myqorzo®? (Aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy

Cytokinetics, Incorporated Announces Positive CHMP Opinion of MYQORZO (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Cytokinetics, Incorporated Appoints Jeffrey J. Hessekiel as Executive Vice President, Chief Legal and Administrative Officer, Effective as of November 14, 2025

Cytokinetics, Incorporated Presents Additional Data from MAPLE-HCM at Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

Third quarter 2025 earnings: EPS and revenues miss analyst expectations

Bronstein, Gewirtz & Grossman Llc Announces That Cytokinetics, Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Insider notifies of intention to sell stock

Insider recently sold US$405k worth of stock

Cytokinetics, Incorporated Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025

Levi & Korsinsky, LLP Files a Complaint to Recover Losses Suffered by Purchasers of Cytokinetics, Incorporated Common Stock and Sets A Lead Plaintiff Deadline of November 17, 2025

Cytokinetics, Incorporated Provides Update on New Drug Application for Aficamten in Obstructive Hectrophic Cardiomyopathy

New minor risk - Share price stability

Cytokinetics, Incorporated Presents New Data Related to Aficamten At the European Society of Cardiology Congress 2025

Cytokinetics Appoints Jim Daly to Board of Directors and as A Member of Compliance Committee Effective August 19, 2025

Consensus revenue estimates increase by 276%

Precision Medicine And Late-stage Trials Will Expand Global Reach

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Cytokinetics, Incorporated to Report Q2, 2025 Results on Aug 07, 2025

Insider notifies of intention to sell stock

The Cytokinetics, Incorporated (NASDAQ:CYTK) Analysts Have Been Trimming Their Sales Forecasts

Cytokinetics, Incorporated Presents Additional Data Related to Aficamten At the European Society of Cardiology Heart Failure 2025 Congress

Cytokinetics, Incorporated Announces Positive Topline Results from MAPLE-HCM

Consensus revenue estimates decrease by 34%, EPS upgraded

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Cytokinetics, Incorporated Announces U.S. Food and Drug Administration Extension of Prescription Drug User Fee Act (PDUFA) Action Date for Aficamten to December 26, 2025

Cytokinetics, Incorporated to Report Q1, 2025 Results on May 06, 2025

Cytokinetics, Incorporated, Annual General Meeting, May 14, 2025

CEO, President & Director recently sold US$611k worth of stock

Cytokinetics, Incorporated Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community

Executive VP & Chief Commercial Officer exercised options and sold US$457k worth of stock

Cytokinetics, Incorporated Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo

Executive VP & Chief Commercial Officer recently sold US$1.2m worth of stock

Cytokinetics Nears Approval: 'Buy' The New Potential Cardiology Franchise With Aficamten

CEO, President & Director recently sold US$1.5m worth of stock

Consensus revenue estimates fall by 26%

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cytokinetics, Incorporated has filed a Follow-on Equity Offering in the amount of $500 million.

Consensus revenue estimates decrease by 16%

Cytokinetics, Incorporated to Report Q4, 2024 Results on Feb 27, 2025

Cytokinetics, Incorporated Announces the Appointment of Robert E. Landry to Its Board of Directors

Consensus revenue estimates increase by 18%

Cytokinetics Announces Start of AMBER-HFpEF, A Phase 2 Clinical Trial of CK-586 in Patients with Symptomatic Heart Failure with Preserved Ejection Fraction

Cytokinetics Aligns For U.S. Launch Amid HCM Market Evolution

Consensus revenue estimates increase by 23%

Cytokinetics, Incorporated Announces Start of COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction

Cytokinetics, Incorporated Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Consensus revenue estimates increase by 47%, EPS downgraded

Cytokinetics, Incorporated Presents Additional Data from GALACTIC-HF At the American Heart Association Scientific Sessions 2024

Cytokinetics, Incorporated Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy At the American Heart Association Scientific Sessions 2024

Cytokinetics: On The Cusp Of Commercialization

Consensus revenue estimates fall by 14%

Cytokinetics, Incorporated Announces Initiation of Phase 1 Clinical Study of CK-4015089

Now 20% overvalued after recent price rise

Third quarter 2024 earnings: EPS and revenues miss analyst expectations